Clinical Trial Update: Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating darolutamide with or without radiation therapy for metastatic castration-resistant prostate cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Darolutamide (Nubeqa) (darolutamide)

Snippet

Sponsor: UNICANCER | Conditions: Prostatic Cancer, Castration-Resistant | Phase 3 | Status: RECRUITING